Ovid Therapeutics

After epilepsy setback, Ovid charges confidently ahead in CNS
Pharma Voice
Fri, 09/20/24 - 10:27 am
Ovid Therapeutics
R&D
Neuroscience
Takeda
Takeda flunks pivotal epilepsy tests but mulls path to market for Ovid-partnered prospect
Fierce Biotech
Mon, 06/17/24 - 11:29 am
Takeda
clinical trials
Ovid Therapeutics
Dravet syndrome
epilepsy
soticlestat
Ovid partners with Waksal startup to develop drugs for rare brain disorders
BioPharma Dive
Tue, 05/2/23 - 11:50 am
Ovid Therapeutics
Graviton Biosciences
drug development
brain disorders
3 biotech executives on the year ahead: deals, drug pricing and the down market
BioPharma Dive
Thu, 01/19/23 - 07:46 pm
JPMHC 2023
LifeMine
Ovid Therapeutics
Abio-X
Pharma CEOs
Ovid takes a novel approach to gene therapy
EP Vantage
Thu, 08/25/22 - 10:54 am
Ovid Therapeutics
gene therapy
epilepsy
phages
'Stay alive': Wave of layoffs crashes into biotech startup inferno
Fierce Biotech
Mon, 03/28/22 - 10:38 am
biotech
layoffs
startups
Zosano Pharma
Ovid Therapeutics
Passage Bio
Athenex
Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X
Fierce Biotech
Tue, 02/8/22 - 10:02 am
Ovid Therapeutics
gaboxadol
Healx
Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline
Pharmaceutical Business Review
Tue, 01/4/22 - 10:16 am
Ovid Therapeutics
AstraZeneca
small molecule drugs
epilepsy
Ovid shuffles C-suite, lays off staff in wake of PhIII Angelman syndrome fail
Endpoints
Fri, 07/9/21 - 10:11 am
Ovid Therapeutics
Angelman Syndrome
clinical trials
Ovid cuts its losses on controversial Angelman syndrome drug, making its crushing development halt permanent
Endpoints
Mon, 04/19/21 - 11:17 am
Ovid Therapeutics
Angelman Syndrome
OV101
Ovid crashes out in Angelman syndrome
EP Vantage
Wed, 12/2/20 - 10:25 am
Ovid Therapeutics
OV101
clinical trials
Angelman Syndrome
Ovid shows mixed results on epilepsy program
Endpoints
Wed, 09/30/20 - 10:49 pm
Ovid Therapeutics
clinical trials
epilepsy
Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?
Endpoints
Tue, 08/25/20 - 09:57 pm
Ovid Therapeutics
clinical trials
Takeda
Dravet syndrome
Lennox-Gastaut Syndrome
GW Pharma
Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma
Xconomy
Mon, 07/13/20 - 11:06 am
Ovid Therapeutics
Angelman Syndrome
Angelini Pharma
Europe
clinical trials
Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward
Endpoints
Fri, 05/8/20 - 10:34 am
Ovid Therapeutics
Takeda
Lundbeck
Fragile X syndrome
clinical trials
Top Companies in Pharm Country Ranked by Revenue
BioSpace
Fri, 02/7/20 - 11:46 pm
Connecticut
New York
New Jersey
Pennsylvania
Rhode Island
Merck
Bristol-Myers Squibb
Regeneron
Ipsen
Ovid Therapeutics
Codagenix
With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite
Xconomy
Mon, 11/18/19 - 11:43 pm
Ovid Therapeutics
Jason Tardio
Novartis
Jeremy Levin
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 04/28/19 - 10:00 pm
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Positive Results For Ovid Drug, But Questions Remain
Forbes
Mon, 08/6/18 - 10:01 am
Angelman Syndrome
Ovid Therapeutics
gaboxadol
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
CP Wire
Wed, 07/18/18 - 10:00 am
Takeda
Ovid Therapeutics
TAK-935/OV935

Pages